MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

Xue, Zheng; Vis, Daniel J; Bruna, Alejandra; Sustic, Tonci; van Wageningen, Sake; Batra, Ankita Sati; Rueda, Oscar M; Bosdriesz, Evert; Caldas, Carlos; Wessels, Lodewyk F A; Bernards, René

Xue, Zheng; Vis, Daniel J; Bruna, Alejandra; Sustic, Tonci; van Wageningen, Sake; Batra, Ankita Sati; Rueda, Oscar M; Bosdriesz, Evert; Caldas, Carlos; Wessels, Lodewyk F A; Bernards, René.

Afiliación

Xue Z; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Vis DJ; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Bruna A; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Sustic T; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
van Wageningen S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Batra AS; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Rueda OM; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Bosdriesz E; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Caldas C; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Wessels LFA; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, UK.
Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.

Cell Res ; 28(7): 719-729, 2018 07.

Article en En | MEDLINE | ID: mdl-29795445

Asunto(s)

Neoplasias de la Mama/tratamiento farmacológico; Neoplasias del Colon/tratamiento farmacológico; Resistencia a Antineoplásicos/genética; MAP Quinasa Quinasa 4/genética; Quinasa 1 de Quinasa de Quinasa MAP/genética; Neoplasias de la Próstata/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/uso terapéutico; Animales; Bencimidazoles/farmacología; Bencimidazoles/uso terapéutico; Neoplasias de la Mama/genética; Línea Celular Tumoral; Neoplasias del Colon/genética; Femenino; Xenoinjertos; Humanos; Mutación con Pérdida de Función; MAP Quinasa Quinasa 4/antagonistas & inhibidores; Quinasa 1 de Quinasa de Quinasa MAP/antagonistas & inhibidores; Sistema de Señalización de MAP Quinasas/efectos de los fármacos; Masculino; Ratones Endogámicos BALB C; Ratones Desnudos; Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores; Neoplasias de la Próstata/genética; Inhibidores de Proteínas Quinasas/farmacología

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Neoplasias de la Mama / Neoplasias del Colon / Resistencia a Antineoplásicos / Quinasa 1 de Quinasa de Quinasa MAP / MAP Quinasa Quinasa 4 / Inhibidores de Proteínas Quinasas Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Cell Res Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google